Madrigal Pharmaceuticals Inc expected to post a loss of $7.53 a share - Earnings Preview

Madrigal Pharmaceuticals

05/08/2024 18:00

* Madrigal Pharmaceuticals Inc  MDGL.OQ   MDGL.O  is
expected
to show a rise in quarterly revenue when it reports  results on
August 7 for the period ending June 30 2024
    * The West Conshohocken Pennsylvania-based  company is
expected to
report revenue of $3.903 million, according to the mean estimate
from 13 analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Madrigal Pharmaceuticals
Inc
is for a loss of $7.53 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Madrigal
Pharmaceuticals Inc is $385.00​, above​ its last closing price
of $275.36. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -6.15       -6.28      -7.38     Missed  -17.4
 Dec. 31 2024  -5.31       -5.28      -5.68     Missed  -7.5
 Sep. 30 2023  -4.98       -4.93      -5.34     Missed  -8.4​
 Jun. 30 2023  -4.62       -4.58      -4.69     Missed  -2.4
 ​​Mar.        -4.88       -4.94      -4.23     Beat    14.3
 31 2023                                                
 Dec. 31 2022  -4.35       -4.56      -4.98     Missed  -9.3​
 Sep. 30 2022  -4.20       -4.15      -4.75     Missed  -14.4
 Jun. 30 2022  -3.69       -3.70      -4.14     Missed  -12
 This summary was machine generated August 5 at 17:00 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)